Aromatase inhibitors substantially reduce risk of death in ER-positive breast cancer
the ONA take:
According to a study published in the journal The Lancet, researchers have found that aromatase inhibitors significantly decrease the risk of death in postmenopausal women with estrogen receptor-positive breast cancer.
For the meta-analysis, researchers analyzed data from 31,920 postmenopausal women with estrogen receptor-positive early breast cancer. Researchers compared the impact of aromatase inhibitor treatment with tamoxifen treatment on breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality.
Results showed that aromatase inhibitors reduce recurrence rates by approximately 30% more than with tamoxifen. Researchers found that 5 years of aromatase inhibitor treatment decreases 10-year breast cancer mortality by about 15% more than with 5 years of tamoxifen, and by about 40% more compared with no endocrine treatment at all.
"Our global collaboration has revealed that the risk of postmenopausal women with the most common form of breast cancer dying of their disease is reduced by 40% by taking five years of an aromatase inhibitor - a significantly greater protection than that offered by tamoxifen," lead author Professor Mitch Dowsett, Head of the Academic Department of Biochemistry and of the Centre for Molecular Pathology at The Royal Marsden and The Institute of Cancer Research, London, said.
Aromatase inhibitors significantly decrease the risk of death in postmenopausal women with estrogen receptor-positive breast cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|